Analysts think TGTX stock price could increase by 68%
Aug 08, 2025, 11:25 AM
-5.27%
What does TGTX do
TG Therapeutics, based in Morrisville, North Carolina, develops treatments for B-cell malignancies and autoimmune diseases, with key candidates including Ublituximab, TG-1701, and TG-1801. The company employs 284 people and explores partnership opportunities for additional products.
10 analysts think TGTX stock price will increase by 68.26%. The current median analyst target is $46.92 compared to a current stock price of $27.89. The lowest analysts target is $11.11 and the highest analyst target is $57.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
